July 21, 2022
The North American Menopause Society (NAMS) recently released its 2022 Guidelines for Hormone Therapy, an update to its 2017 statement that includes significant additions based on the most current scientific evidence. To provide comprehensive and verified guidelines, NAMS recruited an Advisory Panel of experts in the field to review its 2017 Position Statement, evaluate new literature, assess the evidence, and develop updated recommendations.
The 2022 Hormone Therapy Position Statement reflects the latest research findings and recommendations, further clarifies the balance of risks and benefits of hormone therapy, and provides guidance on additional aspects of health care management relevant to patients experiencing menopause symptoms.
March 25, 2021
Over the past few decades, the scientific community has shed some light on the vast differences between male and female patient health with an increasing focus on female cardiovascular disease pathology. The reason underlying varying reactions to the same diseases between men and women has been related to the brain, and in particular, sex hormones. Testosterone and estrogen are not only vital to fertility and reproductive functions, but they also play a critical role in brain health, and in particular sex-based risk factors associated with neurodegenerative disease. Emerging research reveals that the brains of males and females are much less different in structure than in how they age as well as the effects aging has on their brain health.
November 18, 2019
One of the top causes of disability across the globe, schizophrenia can significantly diminish educational, occupational and psychosocial performance, impairing the lives of millions of people worldwide. Although the severe chronic neurological disorder affects a small proportion of the population – around 1% – it is one of the most disabling conditions, especially if left untreated. Schizophrenia carries a substantial disease burden; people with the disorder face increased risks of premature mortality, suicide, and physical illness.
While research has yet to identify a definitive cause of schizophrenia, many factors are thought to contribute to the development of schizophrenia, including genetics, environment, and neurological changes. Previous research implicates that estrogen may play a significant role in the condition’s progression, with a prior randomized controlled trial revealing symptom improvement in premenopausal female patients treated with transdermal estradiol. These initial positive findings have not been replicated by other studies, including ones without commercial involvement.